ES548135A0 - Un procedimiento para preparar dioxafosforinanos - Google Patents

Un procedimiento para preparar dioxafosforinanos

Info

Publication number
ES548135A0
ES548135A0 ES548135A ES548135A ES548135A0 ES 548135 A0 ES548135 A0 ES 548135A0 ES 548135 A ES548135 A ES 548135A ES 548135 A ES548135 A ES 548135A ES 548135 A0 ES548135 A0 ES 548135A0
Authority
ES
Spain
Prior art keywords
dioxaphosphorinans
preparing
procedure
preparing dioxaphosphorinans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES548135A
Other languages
English (en)
Other versions
ES8701187A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCE-Andeno BV
Oce Andeno BV
Original Assignee
OCE-Andeno BV
Oce Andeno BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OCE-Andeno BV, Oce Andeno BV filed Critical OCE-Andeno BV
Publication of ES548135A0 publication Critical patent/ES548135A0/es
Publication of ES8701187A1 publication Critical patent/ES8701187A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES548135A 1984-10-24 1985-10-23 Un procedimiento para preparar dioxafosforinanos Expired ES8701187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8403224A NL8403224A (nl) 1984-10-24 1984-10-24 Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.

Publications (2)

Publication Number Publication Date
ES548135A0 true ES548135A0 (es) 1986-11-16
ES8701187A1 ES8701187A1 (es) 1986-11-16

Family

ID=19844654

Family Applications (2)

Application Number Title Priority Date Filing Date
ES548135A Expired ES8701187A1 (es) 1984-10-24 1985-10-23 Un procedimiento para preparar dioxafosforinanos
ES554328A Expired ES8704504A1 (es) 1984-10-24 1986-04-24 Un procedimiento para preparar isomeros opticamente activos de dioxafosforinanos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES554328A Expired ES8704504A1 (es) 1984-10-24 1986-04-24 Un procedimiento para preparar isomeros opticamente activos de dioxafosforinanos

Country Status (6)

Country Link
US (1) US4814477A (es)
EP (1) EP0180276B1 (es)
JP (1) JPH0662652B2 (es)
DE (1) DE3567022D1 (es)
ES (2) ES8701187A1 (es)
NL (1) NL8403224A (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP4741725B2 (ja) * 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
HK1043796B (en) 1999-03-05 2007-02-23 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrugs
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
DE60026725T2 (de) * 1999-10-22 2006-09-07 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch aktiven naphthalinderivaten und darin eingesetzte optische resolver
AU1303001A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Process for the production of optically active cyclic enaminone derivatives
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6878831B2 (en) * 2000-12-28 2005-04-12 Takeda Chemical Industries, Ltd. Process for preparing optically active 2,3-dihydrobenzofuran compounds
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US7214668B2 (en) 2002-05-13 2007-05-08 Metabasis Therapeutics, Inc. Phosphonic acid based prodrugs of PMEA and its analogues
AU2003235501A1 (en) 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0315795A (pt) 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
AU2003300434A1 (en) * 2002-12-23 2004-07-22 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN1964967B (zh) 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
AU2005256963A1 (en) * 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
ES2422290T3 (es) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
CN101792398B (zh) * 2010-03-09 2013-06-26 河北科技大学 一种拆分法制备光学纯对羟基苯甘氨酸的方法
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN103232491B (zh) * 2013-02-01 2016-06-15 河北科技大学 一种手性环磷酸的制备方法
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
CN109485561A (zh) * 2018-11-23 2019-03-19 江苏颖盛化工有限公司 一种dl-萘普生的合成工艺
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT951631B (it) * 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.

Also Published As

Publication number Publication date
DE3567022D1 (en) 1989-02-02
NL8403224A (nl) 1986-05-16
ES8704504A1 (es) 1987-04-01
ES8701187A1 (es) 1986-11-16
JPS61103886A (ja) 1986-05-22
EP0180276A1 (en) 1986-05-07
US4814477A (en) 1989-03-21
EP0180276B1 (en) 1988-12-28
JPH0662652B2 (ja) 1994-08-17
ES554328A0 (es) 1987-04-01

Similar Documents

Publication Publication Date Title
ES548135A0 (es) Un procedimiento para preparar dioxafosforinanos
ES551519A0 (es) Un procedimiento para preparar aril-hidroxamatos
ES542051A0 (es) Un procedimiento para preparar derivados de benzoilurea
ES543047A0 (es) Un procedimiento para preparar un derivado de pirimidina
ES545347A0 (es) Un procedimiento para preparar derivados de pirimidina
ES545386A0 (es) Un procedimiento para preparar un organotitanato
MX164160B (es) Un procedimiento para preparar un compuesto neoalcoxi
ES549860A0 (es) Un procedimiento para preparar aminoacil-ladanos
ES543929A0 (es) Un procedimiento para preparar un p-isononanoiloxibenceno- sulfonato
ES548409A0 (es) Un procedimiento para preparar derivados de bencimidazol
ES546157A0 (es) Un procedimiento para preparar quinolonas
ES542149A0 (es) Un procedimiento para preparar hidroxi-4-2h-1-benzotiopiran-2-onas
ES544863A0 (es) Un procedimiento para preparar un compuesto de beta-lactama
ES547419A0 (es) Un procedimiento para preparar derivados de pirimidina
ES544864A0 (es) Un procedimiento para preparar 4-acetoxi-3-hidroxietilazeti-zin-2-ona
ES540784A0 (es) Un procedimiento para preparar compuestos relacionados con espergualina
ES545894A0 (es) Un procedimiento para preparar un derivado de 3-carbonil-1- aminoalquil-1h-indol
ES545111A0 (es) Un procedimiento para preparar un derivado de fluoralilamina
ES546690A0 (es) Un procedimiento para preparar derivados de azirino-pirrolo-indoldiona
ES547458A0 (es) Un procedimiento para preparar derivados de piridiloxi
ES544381A0 (es) Un procedimiento para preparar 5-desoxi-l-arabinosa
ES546669A0 (es) Un procedimiento para preparar compuestos relacionados con histargina
ES553983A0 (es) Un procedimiento para preparar compuestos de piridobenzodiazepina
ES541321A0 (es) Procedimiento para preparar un derivado de fenotiazina
AR241134A1 (es) Un procedimiento para preparar w-lactamas

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303